APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
03 nov. 2022 03h00 HE | invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...